[2015-Jan-30] FDA approves Glyxambi for adults with type 2 diabetes

[2015-Jan-30] FDA approves Glyxambi for adults with type 2 diabetes

http://us.boehringer-ingelheim.com/news_events/press_releases/press_release_archive/2015/2-2-2015-us-fda-approves-first-in-class-glyxambi-empagliflozin-linagliptin-tablets-adults-type-2-diabetes.html

Glyxambi.cdx

R. Grempler, L. Thomas, M. Eckhardt, F. Himmelsbach, A. Sauer, D. E. Sharp, R. A. Bakker, M. Mark, T. Klein and P. Eickelmann, Empagliflozin, a novel selective sodium glucose cotransporter-2 (SGLT-2) inhibitor: characterisation and comparison with other SGLT-2 inhibitors, Diabetes Obes. Metab., 2012, 14 (1), pp 83-90

http://dx.doi.org/10.1111/j.1463-1326.2011.01517.x

Matthias Eckhardt, Elke Langkopf, Michael Mark, Moh Tadayyon, Leo Thomas, Herbert Nar, Waldemar Pfrengle, Brian Guth, Ralf Lotz, Peter Sieger, Holger Fuchs and Frank Himmelsbach, 8-(3-(R)-Aminopiperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylmethyl)-3,7-dihydropurine-2,6-dione (BI 1356), a Highly Potent, Selective, Long-Acting, and Orally Bioavailable DPP-4 Inhibitor for the Treatment of Type 2 Diabetes, J. Med. Chem., 2007, 50 (26), pp 6450–6453

http://dx.doi.org/10.1021/jm701280z